Sinequa

AstraZeneca Success Story with Sinequa: Cognitive Search and Analytics Platform

As a leading biopharmaceutical company, ever wonder how you could unify your siloed data across geographies and business units to extract valuable & contextual insights? For AstraZeneca, accuracy, efficiency, and real-time results and insights were priorities to foster cooperation in R&D, drive innovation, accelerate research, catalyze drug repositioning and shorten drug time-to-market. This IDC case study report “Agile Information Discovery at …

Bluebee

White paper: Bluebee Data security and compliance

Bluebee offers a global bio-informatics platform to process, analyze, share and store genomics data. With a private cloud service, Bluebee supports users in clinical diagnostics, therapeutics and research with advanced analytics for genomic data driven medicine. Designed for cross-functional teams of clinicians and life science researchers the Bluebee platform effectively centralizes and manages genomics data processes and storage. Bluebee’s multi-layered …

EMBL-EBI

SME Bioinformatics Forum 2017

How can your company make the most of public molecular data resources? Find out at our event for small and medium-sized enterprises (SMEs), 1 November on the Wellcome Genome Campus in Hinxton, Cambridge. You’ll meet experts from EMBL-EBI, the Medicines Discovery Catapult, Open Targets and many others that focus on bioinformatics, biomedical and biotechnology R&D. https://www.ebi.ac.uk/about/events/2017/sme-bioinformatics-forum-2017

BioData World Congress

Interview with the President of the European Institute for Innovation through Health Data

The interview was conducted by the DNAdigest team (dnadigest.org) Dipak Kalra is the President of the European Institute for Innovation through Health Data (i~HD). He is also a Professor of Health Informatics at University College London, and  affiliated with University of Gent. He has worked on the clinical, ethical and legal requirements for electronic health records and on the development of international interoperability standards and will present …

TCS Digital AI

AI in Pharmacovigilance — Re-imagining the ICSR processing

Over the last few decades, we have seen a spurt of medicines approved by regulatory authorities which have necessitated an increase in the need for monitoring drugs. Pharmacovigilance, is an arm of medical science which deals with gathering, monitoring and assessing the safety of drugs. It has gained increased focus and prominence, over the last decade. It’s thus not a …

Re-Imagining Drug Safety Powered by Genomics, Information Integration and Emerging Technologies

|| Whitepaper by Tata Consultancy Services. Pub. 17/08/2017 Abstract Scientific advancements, emerging technologies, and extensive information have created new opportunities for modernizing drug safety.  Simultaneously, the pharmacovigilance regulatory landscape is shifting to ensure improved safety for patients. This is the time to reimagine the  drug safety sector to transform it into an advanced, proactive and patient-centric practice. Introduction The global …

[[Whitepaper]] Development of Robust Processes for Large Scale Antibody-Drug Conjugation

Antibody-drug Conjugates (ADCs) represent a potent therapeutic for targeted delivery of toxins to specific cell types. ADCs are composed of a moncolonal antibody (mAb) conjugated to a drug molecule via a linker. The use of mAbs results in the delivery of the cytotoxic payload to only the targeted cell type, and because of this ADCs have shown promise as an …

Algorics announces latest version of Acuity analytics platform

Algorics announces latest version of Acuity analytics platform enhancing the industry’s first end-to-end platform for Risk Based Monitoring  Acuity now features enhanced site monitoring support, full tracking of insights into actions, and Japanese localization Houston, TX, USA, For Immediate Release: 15 March, 2017. Algorics, a provider of cloud-based innovative clinical analytics solutions and software for the global life sciences industry, …

Pharma Pricing Congress

Hot topics in pharma and orphan drugs

By Christina Poschen I attended this year’s Pharma Pricing and Market Access Conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes in the …

Global Pricing

Pricing pressures in changing market landscapes: tapping the value nexus

|Pati Ladron – Client Solutions Lead at Global Pricing Innovations Published 21th February 2017 Tougher pharmaceutical cost-containment measures are, perhaps, an unsurprising response to an acceleration in the commercialisation of high-cost speciality medicines and to the fiscal pressures engendered by ageing societies and sluggish economic growth. Consequently, research-intensive pharmaceutical companies are under intense pressure to justify the cost of their …